SCHEMBL106356

SCHEMBL106356

CC(=O)OC[C@@]1(C)[C@@H]2C[C@H](OC(C)=O)[C@@]3(C)Oc4cc(-c5cccnc5)oc(=O)c4[C@H](O)[C@@H]3[C@@]2(C)CC[C@@H]1OC(C)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SOAT2 O75908 14/20 1.00
SOAT1 P35610 13/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21003882 1.00 SOAT2 (1.00) SOAT2SOAT1
SCHEMBL19149738 1.00 SOAT2 (1.00) SOAT2SOAT1
SCHEMBL15894812 1.00 SOAT2 (1.00) SOAT2SOAT1
SCHEMBL12315986 1.00 SOAT2 (1.00) SOAT2SOAT1
SCHEMBL12467707 1.00 SOAT2 (1.00) SOAT2SOAT1
SCHEMBL12654001 1.00 SOAT2 (1.00) SOAT2SOAT1
SCHEMBL31376280 1.00 SOAT2 (1.00) SOAT2SOAT1
SCHEMBL18648382 1.00 SOAT2 (1.00) SOAT2SOAT1
SCHEMBL12467442 0.96 SOAT2 (0.92) SOAT2SOAT1
SCHEMBL12467763 0.95 SOAT2 (1.00) SOAT2SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12605359-B2 Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and pharmaceutical use therefor THE KITASATO INSTITUTE (JP) 2026-04-21 US claimed
CN-119265049-B Bacterial strain for producing pyripyropene A and application thereof 鲁东大学 2025-04-01 CN claimed
CN-119265049-A Bacterial strain for producing pyripyropene A and application thereof 鲁东大学 2025-01-07 CN claimed
CN-116904328-B Engineering bacterium for high-expression of pyripyropene A and fermentation medium 山东大学 2024-08-02 CN claimed
US-11911469-B2 Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes (CN) 2024-02-27 US claimed
CN-116904328-A Engineering bacterium for high-expression of pyripyropene A and fermentation medium 山东大学 2023-10-20 CN claimed
US-11571400-B2 ACAT1 inhibitors for treating cancer CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) 2023-02-07 US claimed
CN-106032383-B A kind of tricyclic analog, preparation method and use 中国科学院上海药物研究所 2019-08-13 CN claimed
EP-2945949-B1 METHOD FOR PREPARING A PYRIPYROPENE COMPOUND BASF SE (DE) 2019-05-15 EP claimed
US-10278962-B2 Tricyclic analogues, preparation method and uses thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2019-05-07 US claimed
WO-2014205109-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT AND MANAGEMENT OF STEATOSIS IN HUMAN LIVER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2014-12-24 WO claimed
CN-104017839-A Method for manufacturing a pyripyropene MEIJI SEIKA PHARMA CO LTD 2014-09-03 CN claimed
US-20140142289-A1 PYRIPYROPENE A BIOSYNTHETIC GENE MEIJI SEIKA PHARMA CO., LTD. (JP) 2014-05-22 US claimed
CN-103536922-A Application of acyl-coenzyme A: cholesterol acyltransferase-2 (ACAT2) inhibitor in liver cancer growth inhibition SHANGHAI INST BIOL SCIENCES 2014-01-29 CN claimed
EP-2319923-B1 PYRIPYROPENE A BIOSYNTHETIC GENES MEIJI SEIKA PHARMA CO LTD (JP) 2013-12-25 EP claimed
US-8557550-B2 Pyripyropene a biosynthetic gene Meija Seika Pharma Co., Ltd. (JP) 2013-10-15 US claimed
US-20130023017-A1 METHOD FOR PRODUCING PYRIPYROPENE MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) 2013-01-24 US claimed
EP-2530164-A1 METHOD FOR MANUFACTURING A PYRIPYROPENE Meiji Seika Pharma Co., Ltd. (JP) 2012-12-05 EP claimed
US-20120015410-A1 PYRIPYROPENE A BIOSYNTHETIC GENE MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) 2012-01-19 US claimed
EP-2319923-A1 PYRIPYROPENE A BIOSYNTHETIC GENE Meiji Seika Kaisha, Ltd. (JP) 2011-05-11 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11571400-B2 ACAT1 inhibitors for treating cancer ACAT2, ACAT1, CEPT1 SOAT2 384/4885SOAT1 149/4885
US-11911469-B2 Combination of ACAT1 inhibitor and checkpoint antibody for treating cancer CD274, PDCD1, PDCD4 SOAT2 3131/4885SOAT1 1835/4885
US-10278962-B2 Tricyclic analogues, preparation method and uses thereof ACAT2, ACAT1, LCAT SOAT2 19/4885SOAT1 24/4885
US-20120015410-A1 PYRIPYROPENE A BIOSYNTHETIC GENE PNKP, COASY, FDPS SOAT2 2495/4885SOAT1 2684/4885
US-12605359-B2 Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor and pharmaceutical use therefor PCSK9, PCSK7, PCSK6 SOAT2 393/4885SOAT1 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.